CytRx said that its subsidiary RXi Pharmaceuticals has appointed Pamela Pavco as its vice president of pharmaceutical development.
Previously, Pavcoheld various positions at RNAi drug developer Sirna Therapeutics, which was acquired by Merck this year. She holds a PhD in biochemistry from Virginia Commonwealth University, CytRx said.
Invitrogen has appointed Per Peterson to its board of directors.
Peterson recently retired as chairman of research and development at Johnson & Johnson. He holds a BM in medicine and a PhD in medicinal chemistry from the University of Uppsala.